KMB — Kimberly-Clark Corporation

Sentiment is cautious but not bearish. KMB's Q2 2026 adjusted EPS of $2.12 beat consensus, but revenue/guidance were soft, with China quality allegations and $150M of H2 input cost headwinds. As of 2026-08-27, Wall Street is at Hold, price targets cluster around $113-$117, and the stock sits near the middle of its 52-week range with RSI at 51.5.

Revenue has flattened at roughly $4.1-$4.2B per quarter over the last four reported periods, after stepping down from $4.8-$5.1B quarters in 2024/early 2025; Q2 2026 revenue was +0.6% y/y. GAAP operating margin fell to 10.7% in Q2 2026 from ~15% in mid-2025, but this overstates the deterioration because Q2 included charges and adjusted gross margin still expanded 190bps to 38.8%. The trend is mature and flat with cost-driven earnings improvement rather than organic growth.

As of 2026-08-27, KMB's 18.7x trailing GAAP P/E and 14.8x forward P/E are below its 5-year average of 21.5x, and P/S of 2.2x is in line with the 5-year average of 2.18x. The sub-average multiple looks justified by flat revenue, high dividend payout, and M&A uncertainty. On a dividend-discount basis I calculate fair value around $112.80, so the stock is roughly fairly valued rather than clearly cheap.

At $109.98, the market is pricing KMB as a stable income vehicle, not a growth stock. The forward EPS estimate of $7.45 is well above trailing GAAP EPS of $5.88, so the stock's apparent cheapness depends on cost savings and charges fading. If adjusted EPS materializes and China stabilizes, upside toward $115-$120 is plausible; if input costs or Kenvue integration pressure cash flow, the high dividend yield likely cushions downside in the $95-$100 area.

As of 2026-08-27, RSI(14) was 51.5, squarely neutral. Price was 0.35% above the 20-day SMA, 0.66% above the 50-day SMA, and 6.65% above the 200-day SMA. KMB looks range-bound within a $92.42-$131.53 52-week band, with no clear entry trigger; the positive slope versus the 200-day suggests a slow recovery but not momentum.

• KMB expects roughly $150M of oil-related input-cost inflation in H2 2026, pressuring gross margin unless productivity offsets continue.
• Private-label competition in developed markets is limiting pricing power and contributing to flat/negative volumes.
• A 5.13% dividend yield makes KMB an income substitute for bonds; rate cuts or a 10-year yield decline would likely support the stock.
• The pending Kenvue acquisition will alter leverage, share count, and scale, making near-term capital allocation the dominant macro story.
• Strained consumer budgets are keeping category volumes soft, particularly in North America.

• Kenvue acquisition closing by late Q4 2026, which would dramatically reshape KMB's portfolio, debt load, and earnings power.
• Q3 2026 earnings in late October/early November 2026, providing updated China recovery data and input-cost absorption.

• Kenvue integration risk, added leverage, and possible dividend policy changes or share dilution.
• China personal-care disruption from social-media quality allegations could persist longer than expected.
• Re-acceleration of input-cost inflation could pressure adjusted margins.
• Private-label share gains and weak consumer volumes could keep revenue growth at zero or negative.

KMB is a financially sound but no-growth defensive company with a 5.1% dividend yield and a large, uncertain acquisition ahead. As of 2026-08-27, the risk/reward is balanced enough for a clear Neutral: not attractive enough to chase, not weak enough to short, and best suited to an investor who specifically wants low-beta income and can tolerate M&A execution risk.

Fair value estimated using a Gordon growth P/E on forward earnings: dividend per share of $5.64 and next-FY EPS estimate of $7.45 imply a 75.7% payout; applying a 7.0% required return and 2.0% terminal growth gives a justified P/E of 15.1x, or $112.83. This is a standalone, pre-Kenvue estimate—the acquisition would require a new valuation model.